EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3

Gan Wu, Ben Cao, Haige Zhai, Bin Liu, Yuan Huang, Xiaowei Chen, Hanzhi Ling, Sunwang Ling, Shengwei Jin, Xinyu Yang, Jianguang Wang

Annals of the Rheumatic Diseases · 2024

DOI: 10.1136/ard-2023-224852 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2024. Verfasst von Gan Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia and Critical Care, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhe…. Hauptthemen laut MEDLINE: Arthritis, Experimental, Arthritis, Rheumatoid, Erythropoietin, Neuraminidase. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, National Natural Science Foundation of China Joint Fund Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Erythropoietin (EPO) known as an erythrocyte-stimulating factor is increased in patients with rheumatoid arthritis (RA). Nevertheless, the function of EPO in the process of RA and relative mechanism needs to be further clarified. METHODS: The level of EPO in serum and synovial fluid from patients with RA and healthy controls was determined by . Collagen-induced arthritis (CIA) mice were constructed to confirm the role of EPO on RA pathogenesis. Differentially expressed genes (DEGs) of EPO-treated fibroblast-like synoviocyte (FLS) were screened by transcriptome sequencing. The transcription factor of neuraminidase 3 (NEU3) of DEGs was verified by double luciferase reporting experiment, DNA pulldown, electrophoretic mobility shift assay and chromatin immunoprecipitation-quantitative PCR (qPCR) assay. RESULTS: The overexpression of EPO was confirmed in patients with RA, which was positively associated with Disease Activity Score 28-joint count. Additionally, EPO intervention could significantly aggravate the joint destruction in CIA models. The upregulation of NEU3 was screened and verified by transcriptome sequencing and qPCR in EPO-treated FLS, and signal transducer and activator of transcription 5 was screened and verified to be the specific transcription factor of NEU3. EPO upregulates NEU3 expression via activating the Janus kinase 2 (JAK2)-STAT5 signalling pathway through its receptor EPOR, thereby to promote the desialylation through enhancing the migration and invasion ability of FLS, which is verified by JAK2 inhibitor and NEU3 inhibitor. CONCLUSION: EPO, as a proinflammatory factor, accelerates the process of RA through transcriptional upregulation of the expression of NEU3 by JAK2/STAT5 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, ExperimentalArthritis, RheumatoidErythropoietinNeuraminidaseSynoviocytesAnimalsHumansMiceCell ProliferationCells, CulturedFibroblastsSTAT5 Transcription FactorSynovial Membrane

Stichwörter der Autor:innen

Arthritis, RheumatoidFibroblastsSynovial fluidTherapeutics

Substanzen

ErythropoietinNeuraminidaseSTAT5 Transcription FactorEPO protein, humanNeu3 protein, humanEpo protein, mouseNeu3 protein, mouse

Autor:innen und Institutionen

  • Department of Anesthesia and Critical Care, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Key Laboratory of Pediatric Anesthesiology, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Institute of Autoimmune Diseases, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Immunology and Rheumatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Anesthesia and Critical Care, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China wjg@wmu.edu.cn yangxy@wmu.edu.cn jinshengwei69@163.com.
  • Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China wjg@wmu.edu.cn yangxy@wmu.edu.cn jinshengwei69@163.com.

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • National Natural Science Foundation of China Joint Fund Project
  • Zhejiang Provincial Natural Science Foundation

Zitieren

APA

Wu, G., Cao, B., Zhai, H., Liu, B., Huang, Y., Chen, X., Ling, H., Ling, S., Jin, S., Yang, X., & Wang, J. (2024). EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard-2023-224852

Vancouver

Wu G, Cao B, Zhai H, Liu B, Huang Y, Chen X, et al. EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3. Annals of the Rheumatic Diseases. 2024. doi:10.1136/ard-2023-224852

BibTeX
@article{Wu2024,
  author = {Wu, Gan and Cao, Ben and Zhai, Haige and Liu, Bin and Huang, Yuan and Chen, Xiaowei and Ling, Hanzhi and Ling, Sunwang and Jin, Shengwei and Yang, Xinyu and Wang, Jianguang},
  title = {EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3},
  journal = {Annals of the Rheumatic Diseases},
  year = {2024},
  doi = {10.1136/ard-2023-224852}
}
Kostenlos starten →